Infinity Financial Statements From 2010 to 2025

Infinity Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Infinity Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Infinity Pharmaceuticals financial statements helps investors assess Infinity Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Infinity Pharmaceuticals' valuation are summarized below:
Gross Profit
-26 M
Market Capitalization
908
Revenue
2.6 M
Earnings Share
(0.46)
Quarterly Revenue Growth
(0.15)
There are currently one hundred twenty fundamental trends for Infinity Pharmaceuticals that can be evaluated and compared over time across competitors. Investors and active traders are advised to confirm Infinity Pharmaceuticals' regular fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 02/25/2025, Market Cap is likely to grow to about 84.7 M, while Enterprise Value is likely to drop slightly above 13.3 M.

Infinity Pharmaceuticals Total Revenue

1.84 Million

Check Infinity Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Infinity Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 451 K or Interest Expense of 153.9 K, as well as many indicators such as Price To Sales Ratio of 16.33, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Infinity financial statements analysis is a perfect complement when working with Infinity Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Infinity Pharmaceuticals Correlation against competitors.
To learn how to invest in Infinity Stock, please use our How to Invest in Infinity Pharmaceuticals guide.

Infinity Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets59.2 M48.5 M50.4 M
Pretty Stable
Short and Long Term Debt Total784 K825.3 K3.2 M
Very volatile
Other Current LiabilitiesM9.9 M8.1 M
Slightly volatile
Total Current Liabilities13.1 M15.7 M11.1 M
Slightly volatile
Other Liabilities47.1 M56.3 M37.3 M
Slightly volatile
Property Plant And Equipment Net2.2 M1.3 M3.2 M
Slightly volatile
Current Deferred Revenue7.9 M7.8 MM
Slightly volatile
Accounts Payable3.1 M5.1 M2.4 M
Slightly volatile
Cash46.7 M44.1 M31.2 M
Slightly volatile
Non Current Assets Total2.4 M1.7 M3.6 M
Slightly volatile
Non Currrent Assets Other93.6 K174.6 K179.1 K
Slightly volatile
Other Assets252.8 K316.8 K434.7 K
Slightly volatile
Long Term Debt36.6 M56 M34.8 M
Slightly volatile
Cash And Short Term Investments53.8 M44.1 M44.6 M
Pretty Stable
Common Stock Shares Outstanding80.2 M102.6 M67.3 M
Slightly volatile
Liabilities And Stockholders Equity59.2 M48.5 M50.4 M
Pretty Stable
Non Current Liabilities Total49.6 M54.7 M38.5 M
Slightly volatile
Capital Lease Obligations277 K291.6 K1.5 M
Slightly volatile
Other Current Assets1.5 M1.8 MM
Slightly volatile
Other Stockholder Equity865.3 M962.3 M775.8 M
Slightly volatile
Total Liabilities62.7 M70.4 M49.6 M
Slightly volatile
Property Plant And Equipment Gross4.3 M4.3 M5.4 M
Slightly volatile
Total Current Assets55.9 M46.3 M46.7 M
Pretty Stable
Capital Stock82.2 K102.3 K67.8 K
Slightly volatile
Non Current Liabilities Other42.4 M54.3 M35.3 M
Slightly volatile
Net Working Capital42.8 M30.7 M35.6 M
Very volatile
Short Term DebtM682 K591 K
Slightly volatile
Common Stock82.2 K102.3 K67.8 K
Slightly volatile
Property Plant Equipment2.5 M2.1 M3.4 M
Slightly volatile
Short and Long Term Debt959.8 KM875.6 K
Slightly volatile

Infinity Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization451 K526.7 K315.4 K
Slightly volatile
Interest Expense153.9 K162 K1.8 M
Slightly volatile
Selling General Administrative10.9 M12.1 M13.7 M
Slightly volatile
Total Revenue1.8 M2.3 M2.7 M
Slightly volatile
Other Operating Expenses50.4 M54.6 M48.4 M
Very volatile
Research Development32.4 M37.3 M29 M
Slightly volatile
Cost Of Revenue2.2 M1.4 M5.1 M
Slightly volatile
Total Operating Expenses47.4 M52.8 M43.2 M
Slightly volatile
Reconciled Depreciation451 K526.7 K315.4 K
Slightly volatile

Infinity Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2.7 M4.2 M2.5 M
Slightly volatile
Begin Period Cash Flow49.8 M93 M52.6 M
Slightly volatile
Depreciation451 K526.7 K315.4 K
Slightly volatile
Capital Expenditures14.5 K15.3 K1.5 M
Slightly volatile
Issuance Of Capital Stock79.8 K84 KM
Pretty Stable
Total Cash From Financing Activities62.4 K65.7 K24.5 M
Slightly volatile
End Period Cash Flow47 M44.2 M31.5 M
Slightly volatile
Change To Netincome2.3 M2.3 M3.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio16.3317.1926.7887
Pretty Stable
Stock Based Compensation To Revenue0.881.260.8891
Slightly volatile
Capex To Depreciation0.04060.04276.6578
Slightly volatile
EV To Sales5.115.3816.6036
Pretty Stable
Payables Turnover0.390.412.964
Slightly volatile
Sales General And Administrative To Revenue4.944.675.107
Slightly volatile
Research And Ddevelopement To Revenue10.811.2510.5365
Slightly volatile
Capex To Revenue0.00720.00750.4807
Slightly volatile
Cash Per Share0.740.490.6906
Slightly volatile
Days Payables Outstanding583926386
Slightly volatile
Income Quality0.720.860.8811
Pretty Stable
Net Debt To EBITDA0.640.770.5959
Slightly volatile
Current Ratio4.683.44.3381
Slightly volatile
Graham Number2.01.781.6807
Slightly volatile
Capex Per Share2.0E-42.0E-40.0256
Slightly volatile
Revenue Per Share0.03650.03340.0446
Slightly volatile
Interest Debt Per Share0.01340.01410.0849
Pretty Stable
Debt To Assets0.02380.0250.0736
Very volatile
Price Earnings To Growth Ratio0.150.180.1766
Pretty Stable
Days Of Payables Outstanding583926386
Slightly volatile
Ebt Per Ebit1.121.141.0382
Slightly volatile
Quick Ratio4.683.44.3381
Slightly volatile
Net Income Per E B T0.80.90.9802
Slightly volatile
Cash Ratio2.752.532.6571
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0514
Very volatile
Fixed Asset Turnover1.641.560.9895
Slightly volatile
Debt Ratio0.02380.0250.0736
Very volatile
Price Sales Ratio16.3317.1926.7887
Pretty Stable
Asset Turnover0.0520.07070.0583
Pretty Stable

Infinity Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap84.7 M57 M60.3 M
Pretty Stable
Enterprise Value13.3 M14 M33.3 M
Pretty Stable

Infinity Fundamental Market Drivers

Cash And Short Term Investments38.3 M

About Infinity Pharmaceuticals Financial Statements

Infinity Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Infinity Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Infinity Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Infinity Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue7.8 M7.9 M
Total Revenue2.3 M1.8 M
Cost Of Revenue1.4 M2.2 M
Stock Based Compensation To Revenue 1.26  0.88 
Sales General And Administrative To Revenue 4.67  4.94 
Research And Ddevelopement To Revenue 11.25  10.80 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.03  0.04 
Ebit Per Revenue(19.89)(20.88)

Pair Trading with Infinity Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Infinity Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Infinity Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Infinity Stock

  0.77GANX Gain TherapeuticsPairCorr
  0.75PFE Pfizer Inc Aggressive PushPairCorr
  0.7PHGE Biomx IncPairCorr
  0.68OPT Opthea Earnings Call TomorrowPairCorr
  0.65CUE Cue BiopharmaPairCorr
The ability to find closely correlated positions to Infinity Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Infinity Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Infinity Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Infinity Pharmaceuticals to buy it.
The correlation of Infinity Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Infinity Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Infinity Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Infinity Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Infinity Stock Analysis

When running Infinity Pharmaceuticals' price analysis, check to measure Infinity Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infinity Pharmaceuticals is operating at the current time. Most of Infinity Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Infinity Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infinity Pharmaceuticals' price. Additionally, you may evaluate how the addition of Infinity Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.